Michael Regan
About Michael Regan
Michael Regan is SHF Holdings’ Chief Investment & Strategy Officer, appointed September 24, 2025, after joining the company in March 2025 and serving as Head of Investor Relations & Data Science (March–June 2025) and Vice President, Strategic Finance & Corporate Development (June–September 2025) . He brings 13 years of hedge fund experience (Roubaix Capital, Hawkshaw Capital, Copper Arch Capital) and 5 years at investment banks (Excelsior Equities, Deutsche Bank, Credit Suisse, DLJ), with a BS in Business Administration (Georgetown) and MBA from MIT Sloan; age 48; FINRA Series 7, 24, 86, 87 licenses (inactive; exp. 2026) . Company-level TSR, revenue growth and EBITDA growth tied to his tenure are not specifically disclosed in these filings and thus omitted.
Past Roles
| Organization | Role | Years | Strategic Impact |
|---|---|---|---|
| SHF Holdings, Inc. | Chief Investment & Strategy Officer | Appointed Sep 24, 2025 | Leads capital markets, strategy; newly created executive role |
| SHF Holdings, Inc. | VP, Strategic Finance & Corporate Development | Jun–Sep 2025 | Corporate finance and development responsibilities |
| SHF Holdings, Inc. | Head of Investor Relations & Data Science | Mar–Jun 2025 | Oversaw IR and data science; insider policy consent authority cited in proxy |
| Excelsior Equities, LLC | Director of Research & Founding Partner | Dec 2022–Dec 2024 | Research leadership and firm-building |
| MJResearchCo LLC | Founder | May 2020–Dec 2022 | Founded cannabis-focused research firm; consulting to HAL Extraction (Nov 2020–Dec 2022) |
| Roubaix Capital; Hawkshaw Capital; Copper Arch Capital | Hedge funds (investment roles) | 13 years (cumulative) | Capital markets and investment experience |
| Excelsior Equities; Deutsche Bank; Credit Suisse; DLJ | Investment banking (various roles) | 5 years (cumulative) | Corporate finance and markets exposure |
External Roles
No public-company board roles or external directorships are disclosed for Regan in the management sections reviewed .
Equity Ownership & Alignment
| Item | Detail | Notes |
|---|---|---|
| Beneficial ownership (common) | 45,875 shares; 1.4% of voting power | Entirely incentive stock options counted as beneficially owned per SEC rules |
| Options – terms | Exercise price $2.40; 10-year term from grant; vested or vest within 60 days | Footnote specifies option composition and vest timing window |
| Shares outstanding reference | 2,953,473 common shares (record date Oct 14, 2025) | Ownership percentage base for beneficial table |
| Hedging policy | Hedging/monetization prohibited without prior written consent from Head of IR & Data Science (Regan at that time) | Company insider trading policy governance |
| Series B Preferred (insider participation) | Regan invested $50,400 for 63 shares of Series B Convertible Preferred Stock | Subject to stockholder approval per Nasdaq Rule 5635(c) |
| Series B Warrants (insider participation) | 4,057 warrants at $7.7644 exercise price | Terms subject to approval; see warrant mechanics below |
| SPA Warrant mechanics | Exercisable 6 months + 1 day from Applicable Date; 3-year expiry; price adjustment to market on set dates; floor price $7.7644 until stockholder approval | Warrant features and adjustments |
| Potential management dilution | Up to 54,869 shares issuable to management participants (aggregate) upon conversion/exercise if proposals adopted | Company-wide management participation effect |
Employment Terms
| Term | Detail |
|---|---|
| Appointment date and role | Appointed Chief Investment & Strategy Officer on Sept 24, 2025 |
| Contract, severance, change-of-control | Not specifically disclosed for Regan in reviewed filings; company-wide equity awards governed by the Amended & Restated 2022 Equity Incentive Plan and clawback policies |
| Insider trading/hedging | Company policy prohibits hedging/monetization absent consent; IR & Data Science head (Regan at the time) designated consent authority |
Related Party Transactions
| Transaction | Regan’s Participation | Terms |
|---|---|---|
| Series B Preferred Stock Offering (SPA) | $50,400 investment; 63 Series B Preferred; 4,057 warrants | Conversion at $7.7644 per $1,000 preferred share; warrants $7.7644 exercise price with adjustment mechanics; requires stockholder approval under Nasdaq rules |
Compensation Structure Notes
- SHF, as a smaller reporting and emerging growth company, discloses NEO pay for 2023–2024 but Regan was not a NEO in those years; specific base salary, target/actual bonus, and equity awards for Regan are not disclosed in the reviewed proxies and S-1/A, so omitted .
Investment Implications
- Alignment: Regan’s insider investment ($50,400) into the Series B financing and associated preferred/warrants signals personal capital at risk and alignment with capital-raising strategy .
- Near-term selling pressure: His option package is in-the-money relative to the Oct 13, 2025 closing price ($3.73 vs $2.40 strike), which could create optionality for exercise; however, warrants at $7.7644 are out-of-the-money at that reference price, limiting near-term warrant exercise pressure .
- Dilution mechanics: Company proposals contemplate material dilution to enable financing—up to 5,998,846 shares to SPA Buyers (if adopted) and up to 54,869 shares to management participants—investors should monitor approvals and issuance pacing; Regan’s participation is a small fraction of aggregate potential issuance .
- Governance and retention: Regan’s rapid internal progression and strategic remit underscore execution focus; lack of disclosed individual severance/change-of-control terms means retention economics are opaque, with equity alignment driven by options and preferred/warrants governed under the plan and clawback policies .